UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hypothalamic Hormones and Cancer

Frontiers in neuroendocrinology, 2001-10, Vol.22 (4), p.248-291

2001

Volltextzugriff (PDF)

Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa

Metabolism, clinical and experimental, 1997-12, Vol.46 (12), p.1384-1389

1997

Volltextzugriff (PDF)

220 Discovery of selective inhibitors of fibroblast growth factor receptor (FGFR): Antitumor activity in cellular and xenograft tumor models with FGFR activation

European journal of cancer supplements, 2010, Vol.8 (7), p.72-72

2010

Volltextzugriff (PDF)

219 PI3K delta: Discovery of potent and selective inhibitors for treating hematopoietic malignancies

European journal of cancer supplements, 2010, Vol.8 (7), p.72-72

2010

Volltextzugriff (PDF)

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

Regulatory peptides, 2002-10, Vol.108 (2), p.47-53

2002

Volltextzugriff (PDF)

Simultaneous Delivery of a Face-to-Face Course to On-Campus and Remote Off-Campus Students

TechTrends, 2010-07, Vol.54 (4), p.34-40

2010

Volltextzugriff (PDF)

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215

British journal of cancer, 2002-04, Vol.86 (8), p.1322-1327

2002

Volltextzugriff (PDF)

Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness

International journal of oncology, 2001-09, Vol.19 (3), p.571

2001

Volltextzugriff (PDF)

Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in vitro: Implications for the Design of Preclinical Studies

Proceedings of the National Academy of Sciences - PNAS, 2000-01, Vol.97 (2), p.829-834

2000

Volltextzugriff (PDF)

Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome

Gynecological endocrinology, 1999, Vol.13 (5), p.344-351

1999

Volltextzugriff (PDF)

Human Renal Cell Carcinoma Expresses Distinct Binding Sites for Growth Hormone-Releasing Hormone

Proceedings of the National Academy of Sciences - PNAS, 2000-09, Vol.97 (19), p.10555-10560

2000

Volltextzugriff (PDF)

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II

Cancer, 2002-10, Vol.95 (8), p.1735-1745

2002

Volltextzugriff (PDF)

Effects of PACAP and VIP on Adrenal Progesterone Release

Annals of the New York Academy of Sciences, 1996-12, Vol.805 (1), p.628-633

1996

Volltextzugriff (PDF)

Peptide analogs in the therapy of prostate cancer

The Prostate, 2000-10, Vol.45 (2), p.158-166

2000

Volltextzugriff (PDF)

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa

European journal of endocrinology, 1995-02, Vol.132 (2), p.147-151

1995

Volltextzugriff (PDF)

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

International journal of cancer, 2000-11, Vol.88 (4), p.652-657

2000

Volltextzugriff (PDF)

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

Cancer research (Chicago, Ill.), 1999-04, Vol.59 (8), p.1947-1953

1999

Volltextzugriff (PDF)

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

Peptides (New York, N.Y. : 1980), 2002-06, Vol.23 (6), p.1127-1133

2002

Volltextzugriff (PDF)

High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers

The journal of clinical endocrinology and metabolism, 2000-07, Vol.85 (7), p.2564-2571

2000

Volltextzugriff (PDF)

Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

International journal of cancer, 2002-04, Vol.98 (4), p.624-629

2002

Volltextzugriff (PDF)

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

Cancer letters, 2002-02, Vol.176 (1), p.57-63

2002

Volltextzugriff (PDF)

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238

Cancer research (Chicago, Ill.), 2000-06, Vol.60 (11), p.2996-3001

2000

Volltextzugriff (PDF)

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

The Prostate, 2000-07, Vol.44 (2), p.172-180

2000

Volltextzugriff (PDF)

Are μ-opioid receptors involved in the control of endothelin-1 release from the pituitary gland in normal and dehydrated rats?

Regulatory peptides, 1997-03, Vol.69 (2), p.89-94

1997

Volltextzugriff (PDF)

Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses

Cancer research (Chicago, Ill.), 1998-09, Vol.58 (18), p.4132-4137

1998

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(86)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hypothalamic Hormones and Cancer

Neuropeptide Y, galanin, and leptin release in obese women and in women with anorexia nervosa

220 Discovery of selective inhibitors of fibroblast growth factor receptor (FGFR): Antitumor activity in cellular and xenograft tumor models with FGFR activation

219 PI3K delta: Discovery of potent and selective inhibitors for treating hematopoietic malignancies

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

Simultaneous Delivery of a Face-to-Face Course to On-Campus and Remote Off-Campus Students

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215

Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness

Stability of Cytotoxic Luteinizing Hormone-Releasing Hormone Conjugate (AN-152) Containing Doxorubicin 14-O-Hemiglutarate in Mouse and Human Serum in vitro: Implications for the Design of Preclinical Studies

Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome

Human Renal Cell Carcinoma Expresses Distinct Binding Sites for Growth Hormone-Releasing Hormone

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: Effects on insulin-like growth factor II

Effects of PACAP and VIP on Adrenal Progesterone Release

Peptide analogs in the therapy of prostate cancer

Impaired response of atrial natriuretic peptide to acute water load in obesity and in anorexia nervosa

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238

Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers

High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers

Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

Are μ-opioid receptors involved in the control of endothelin-1 release from the pituitary gland in normal and dehydrated rats?

Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses

Suchergebnisse filtern